Research and Development: Page 2

Twist Bioscience, Ono Pharmaceutical to collaborate on autoimmune disease drug development

Synthetic biology and genomics company Twist Bioscience has entered into a collaboration with Ono Pharmaceutical, one of the largest pharmaceutical companies in Japan, to discover and develop drugs for autoimmune diseases.

September 5, 2023

RNA exporters enable nondestructive cell monitoring, delivery of therapeutics

RNA exporters could enable the nondestructive monitoring of cells over time and the targeted delivery of mRNA therapeutics, according to a paper published recently in Cell.

September 5, 2023

Oral therapy combination yields promising results in multiple myeloma study

A new agent that can be taken once daily in pill form showed promising results in a clinical trial when used in combination with a steroid in patients with multiple myeloma who had relapsed and stopped responding to currently available therapies.

September 1, 2023

Day Zero Diagnostics awarded SBIR grant to develop fecal transplant safety assay

Boston-based Day Zero Diagnostics is receiving research funding to support the development of a pharmacovigilance assay to enhance the safety and efficacy of fecal microbiota transplants (FMT) in clinical trials.

September 1, 2023

Grail partners with LGBTQ+ group on study of cancer detection blood test

Grail has partnered with the Whitman-Walker Institute and the Cancer Support Community to assess the feasibility of using its multicancer early detection (MCED) Galleri blood test in a real-world setting.

September 1, 2023

Roche data release raises hopes TIGIT drugs can improve lung cancer survival

Roche's inadvertent release of interim data from its ongoing late-phase clinical trial has raised hopes that its anti-TIGIT immunotherapy may improve the survival rate of lung cancer patients.

August 25, 2023

Astellas snags chance to license Poseida cell therapy in $50M deal

The agreement gives Astellas first refusal for partnering on P-MUC1C-ALLO1, an allogeneic chimeric antigen receptor (CAR) T cell therapy product candidate that Poseida is developing as a treatment for solid tumors.

August 9, 2023

Viral vector-based decoy receptors protect mice against COVID-19 infection

Rather than target the viral protein, the researchers proposed introducing a decoy version of the ACE2 protein that SARS-CoV-2 binds to when entering cells.

August 2, 2023

Novel catalyst unlocks new route to synthesis of medicines and advanced materials

The field has lacked a method for consistently creating para-products via the Friedel−Crafts reaction. The Chiba University team addressed this unmet need by using a novel enzyme to modify the reaction to favor the generation of para-substituted products.

July 28, 2023

Co-Diagnostics awarded over $2M from Bill & Melinda Gates Foundation for TB and HPV tests

Dwight Egan, CEO of Co-Diagnostics, said the grants would help support the worldwide effort to prevent the spread of both TB and HPV in countries where they have been endemic killers for generations.

July 26, 2023

Pfizer invests $25M to support development of CellCentric’s blood cancer candidate

Evidence of the roles p300 and CBP play in multiple cancers led CellCentric to generate chemical hits against the proteins, ultimately leading to the development of inobrodib.

July 13, 2023

TScan teams with Tempus to develop companion diagnostic for cancer cell therapy

The biotech firm TScan has identified Tempus as a company that can help it select the right treatments for patients. Tempus is the developer of xT CDx, a companion diagnostic that the FDA approved earlier this year.

July 11, 2023

Previous Page

Page 2 of 35

Next Page